ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy

• Status: Completed
• Trial end date: 2016-03-02
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to increase the fraction of patients, who become MRD-negative during consolidation for the non-HR ALL group through individualized intensification of the 6MP-dosage days 30-85.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rigshospitalet, Denmark
• Collaborator: Nordic Society for Pediatric Hematology and Oncology
• Treatments: 6-Mercaptopurine; Mercaptopurine

Criteria

Inclusion Criteria:

• Childhood ALL

• All mandatory biological data are available6

• Written informed consent has been obtained

Exclusion Criteria:

• Mixed lineage ALL

• Pre-treatment with glucocorticosteroids or other antileukemic agents for more than 1 week

• ALL predisposition syndromes

• Previous cancer

• Off protocol administration of additional chemotherapy during induction therapy

• Sexually active females not using contraception

• TPMT-deficiency